GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology. Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders: In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and

When you talk to leaders who make it to GM, franchise head, or the C‑suite in pharma and biotech, a different pattern shows up: sideways moves into new functions, therapeutic areas, or business models that didn’t look like promotions at the time, but turned out to be pivotal.

Rare Disease as a Strategic Growth Engine Rare disease is no longer just a scientific or regulatory story — it is a commercial one. But in rare disease, “the market” is not an abstract concept. It is a small, tightly connected ecosystem of patients, caregivers, advocates, clinicians, and payers who all know each other — and who expect to be true partners. Speaking to many global commercial leader over the last few weeks Patient advocacy has been a re-occurring theme. For glob

For decades, families affected by rare diseases have heard the same heartbreaking message: ‘There is no approved treatment yet.’ In 2026, that story is finally changing. From the first-ever approval for Menkes disease to a landmark FDA policy shift for gene therapies, the rare disease landscape is transforming at a pace never seen before. Here’s what you need to know.